Article
Evaluation of Artificial Intelligence (AI)-based <i>in silico</i> tools for variant classification in clinically actionable NSCLC variants
2024-04-14
Abstract excerpt
<h4>Introduction/Background</h4> Genetic variants beyond FDA-approved drug targets are often identified in non-small cell lung cancer (NSCLC) patients. Although the performances of in silico tools in predicting variant pathogenicity have been analyzed in previous studies, they have not been analyzed for actionable targets of FDA-approved therapies for NSCLC. The aim of this study is to compare the performance of...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0f7dc144-781c-52f6-b7c6-d85f93c5fa14
- DOI
- 10.1101/2024.04.12.24305738
